Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, have told DirectorsTalk that it has appointed Richard Amos as International Director of Medical Physics, a non-board position, with effect from 1 November 2016.
Richard joins Advanced Oncotherapy from University College London Hospitals NHS Trust, where he was Operational Lead for Proton Therapy Physics at the Department of Radiotherapy Physics. He is also an honorary senior lecturer at the Department of Medical Physics and Biomedical Engineering at University College London. He was a Senior Medical Physicist at The University of Texas MD Anderson Cancer Center in Houston, and was Medical Physicist in the Department of Radiation Medicine in the proton centre at Loma Linda University Medical Center in California. In 2016, the MD Anderson Cancer Center was ranked No. 1 for cancer treatment in the US. The James M Slater Proton Treatment and Research Center at Loma Linda was the first hospital based US proton treatment centre in the world. Today the centre uses proton beam technology for many types of cancers and has treated more patients than any other proton treatment centre worldwide.
Richard is highly regarded in his field and has had 19 peer-reviewed journal articles published. He has also had 74 abstracts printed and is a regular reviewer and editor of medical journals. He holds a BSc (Hons) in Applied Physics from the University of Coventry and an MSc in Applied Radiation Physics from the University of Birmingham, where he was awarded the European Social Fund Graduate Scholarship.
Commenting, Richard Amos said: “My main research interests centre on the clinical implementation of Proton Beam Therapy (‘PBT’), with a major focus being on developing treatment planning techniques to treat the current UK indication list for PBT and to investigate the potential of PBT for other indications, particularly left-sided breast cancer. I am also interested in investigating methods of optimising PBT plan robustness and minimising uncertainties associated with proton beam delivery. The development of novel imaging techniques to monitor and verify proton dose delivery in vivo is one of my main areas of expertise. The technical advantages of AVO’S LIGHT Accelerator promise unique opportunities to enhance the precision and adaptive characteristics of PBT.”
The company further announces that it has today issued 29,542 new ordinary shares (“New Ordinary Shares”) of 25p in the Company at a subscription price of 135.4 pence per Ordinary Share (being the average closing price over the last three months) to an employee as part of their remuneration package.
Application has been made for the 29,542 Shares to be admitted to trading on AIM (“Admission”) and it is expected that Admission will occur on or about 9 September 2016. The Shares will rank pari passu in all aspects with the existing ordinary shares of the Company.
